A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)
NCT ID: NCT05030506
Last Updated: 2025-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE1
45 participants
INTERVENTIONAL
2021-10-13
2027-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Belzutifan + Lenvatinib
Participants will receive a daily oral dose of 120 mg of belzutifan monotherapy for 3 weeks, followed by a combination of a daily oral dose of 120 mg of belzutifan with a daily oral dose of 20 mg of lenvatinib until progressive disease or discontinuation.
Belzutifan
40 mg tablet administered orally at a dose of 120 mg
Lenvatinib
10 mg capsule administered orally at a dose of 20 mg
Belzutifan + Lenvatinib + Pembrolizumab
Participants will receive an intravenous dose of 400 mg of pembrolizumab once every six weeks for up to 18 infusions (up to 2 years) in combination with a daily oral dose of 120 mg of belzutifan and a daily oral dose of 20 mg of lenvatinib until progressive disease or discontinuation.
Belzutifan
40 mg tablet administered orally at a dose of 120 mg
Pembrolizumab
25 mg/mL solution for Infusion in a single-dose vial administered intravenously at a dose of 400 mg
Lenvatinib
10 mg capsule administered orally at a dose of 20 mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Belzutifan
40 mg tablet administered orally at a dose of 120 mg
Pembrolizumab
25 mg/mL solution for Infusion in a single-dose vial administered intravenously at a dose of 400 mg
Lenvatinib
10 mg capsule administered orally at a dose of 20 mg
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has measurable disease per RECIST 1.1.
* Has adequate organ function.
* Has adequately controlled blood pressure (BP).
* If participants received major surgery or radiation therapy of \>30 Gy, they must have recovered from the toxicity and/or complications from the intervention.
* Has resolution of the toxic effect(s) of the most recent prior therapy.
* Participants receiving bone resorptive therapy must have therapy initiated at least 2 weeks prior to allocation.
* Is Chinese descent, defined as both biological parents and all biological grandparents are of Chinese descent.
Male Participants:
\- Must be willing to use an adequate method of contraception.
Female Participants:
\- Must be a woman of non-childbearing potential (WONCBP) or have a negative urine or serum pregnancy test and must be willing to use an adequate method of contraception.
For Belzutifan + Lenvatinib treatment:
* Has progressed on or after having received systemic treatment for locally advanced or metastatic RCC.
* Has no more than 3 prior systemic regimens for locally advanced or metastatic RCC.
For Belzutifan + Lenvatinib + Pembrolizumab treatment:
\- Has received no prior systemic therapy for advanced RCC.
Exclusion Criteria
* Has any of the following: A pulse oximeter reading \<92%, or requires intermittent supplemental oxygen, or requires chronic supplemental oxygen.
* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
* Has known central nervous system (CNS) metastases and/or carcinomatous meningitis.
* Has clinically significant cardiac disease.
* Has symptomatic pleural effusion.
* Has a history of inflammatory bowel disease.
* Has preexisting ≥Grade 3 gastrointestinal or non-gastrointestinal fistula.
* Has clinically significant hematuria, hematemesis or hemoptysis of red blood, or other history of significant bleeding within 3 months before administration of the first dose of study intervention.
* Has other clinically significant disorders such as: A serious active non-healing wound/ulcer/bone fracture, requirement for hemodialysis or peritoneal dialysis or a history of allogenic tissue/solid organ transplantation.
* Received colony-stimulating factors, granulocyte macrophage colony-stimulating factor (GMCSF) or recombinant EPO within 28 days prior to the first dose of study intervention.
* Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study.
* Is unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption.
* Has received prior treatment with belzutifan.
* Has received prior treatment with lenvatinib.
* Has received any type of systemic anticancer antibody (including investigational antibody) ≤28 days prior to allocation.
* Has received / will be receiving any traditional Chinese medicines.
* Has received prior radiotherapy within 2 weeks prior to first dose of study intervention. Participants must have recovered from all radiation-related toxicities and not require corticosteroids.
* Is receiving concomitant treatment, in therapeutic doses, with anticoagulants.
* Is receiving chronic systemic steroids therapy (at doses \>10 mg daily of prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention.
* Is currently participating in a study of an investigational agent or is currently using an investigational device.
* Has an active infection requiring systemic therapy.
* Has a known history of Human Immunodeficiency Virus (HIV) infection.
* Has a known history of Hepatitis B or known active Hepatitis C virus infection.
* Has a known history of active tuberculosis.
* Has radiographic evidence of intratumoral cavitation, encasement or invasion of a major blood vessel.
* Has known hypersensitivity or allergy to the active pharmaceutical ingredient or any component of the study intervention (belzutifan or lenvatinib) formulations.
* Has had major surgery within 4 weeks prior to first dose of study intervention.
For Belzutifan + Lenvatinib + Pembrolizumab treatment:
* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
* Has a history of hypersensitivity reaction to the active pharmaceutical ingredient or any component of pembrolizumab or monoclonal antibody (mAb).
* Has an active autoimmune disease that has required systemic treatment in the past 2 years.
* Has received a live vaccine within 30 days prior to the first dose of study intervention.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Cancer hospital-Digestive Oncology ( Site 0001)
Beijing, Beijing Municipality, China
SUN YAT-SEN UNIVERSITY CANCER CENTRE-Urology Surgery Department ( Site 0005)
Guangzhou, Guangdong, China
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Urology ( S
Nanjing, Jiangsu, China
Tianjin Medical University Cancer Institute and Hospital ( Site 0003)
Tianjin, Tianjin Municipality, China
The Second Affiliated hospital of Zhejiang University school of medicine-Urology ( Site 0007)
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK-6482-010
Identifier Type: OTHER
Identifier Source: secondary_id
6482-010
Identifier Type: -
Identifier Source: org_study_id